Davigatrán vs rivaroxabán en la prevención del tromboembolismo venoso en cirugía electiva de remplazo articular de cadera o de rodilla, del 1 de febrero al 31 de julio del 2013 en el Hospital Eugenio Espejo y Hospital Clínicas Pichincha de Quito - Ecuador.
Thromboembolic events in joint replacement, are a source of concern to the orthopedic surgeon, putting at risk the lives of the patient, the new oral anticoagulants, dabigatran and rivaroxaban thromboprophylaxis in facilitating discharge. This study is observational, and aims to know that medicine i...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | masterThesis |
| Jazyk: | spa |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | http://dspace.unl.edu.ec/jspui/handle/123456789/18744 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Přidat tag | Shrnutí: | Thromboembolic events in joint replacement, are a source of concern to the orthopedic surgeon, putting at risk the lives of the patient, the new oral anticoagulants, dabigatran and rivaroxaban thromboprophylaxis in facilitating discharge. This study is observational, and aims to know that medicine is more effective thromboprophylaxis in replacement patients scheduled for primary hip or knee in hospitals Eugenio Espejo Hospital and Clinics Pichincha Quito during February to July 2013, for which information from the medical records of 80 patients on a sheet of data collection, I was collected from 40 patients were administered dabigatran 220mg Vo QD and 40 were given rivaroxaban 10mg Vo QD, the results indicate that therefore Dabigatran as Rivaroxaban are effective thromboprophylaxis, however Rivaroxaban has a nonsignificant favorable trend in the prevention of distal venous thrombosis (95% - P = 0.25), but simultaneously with an increased risk of minor bleeding (95 % - P = 0.05), although not statistically significant. Key words: New oral anticoagulants (NACO), Dabigatran, Rivaroxaban. |
|---|